{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-079597","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.828956+00:00","generated_at":"2026-06-04T06:27:36.773997+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Invivyd reports FY2023 net loss $198.6M; obtains EUA for PEMGARDA COVID-19 PrEP","bullets":["Net loss $198.6M ($1.81/share) vs $241.3M ($2.23/share) in 2022; R&D expenses $163.6M.","Cash & equivalents $200.6M as of Dec 31, 2023; expects runway into Q4 2024 (excl. PEMGARDA sales).","Received EUA on Mar 22, 2024 for PEMGARDA (pemivibart) for COVID-19 PrEP in immunocompromised patients.","Raised $40.5M in gross proceeds from ATM facility in Feb 2024 to strengthen balance sheet ahead of launch.","Nominated VYD2311 as next SARS-CoV-2 mAb candidate; expects streamlined FDA development pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-079597","json":"https://secwatch.observer/filing/0001193125-24-079597.json","markdown":"https://secwatch.observer/filing/0001193125-24-079597.md","text":"https://secwatch.observer/filing/0001193125-24-079597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524079597/0001193125-24-079597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524079597/d803546d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:27:36.773997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"223a3b0988b112b969fc115e79442be6800cc28a","claim":"Invivyd, Inc. reported the year ended December 31, 2023 results: net income Net loss was $198.6 million for the year ended December 31, 2023, EPS Basic and diluted net loss per share was $1.81 for the year ended December 31, 2023.","evidence_excerpt":"Invivyd, Inc. (the \"Company\") issued a press release announcing its financial results for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524079597/0001193125-24-079597-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $198.6 million for the year ended December 31, 2023"},{"label":"EPS","value":"Basic and diluted net loss per share was $1.81 for the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}